Three-Month Outcomes in Cancer Patients with Superficial or Deep Vein Thrombosis in the Lower Limbs

The natural history of isolated lower-limb superficial vein thrombosis (SVT) in cancer patients is not well understood. To address this gap, we analyzed data from the RIETE registry, which included 110 cancer patients with isolated SVT, 1695 cancer patients with isolated deep vein thrombosis (DVT),...

Descripción completa

Detalles Bibliográficos
Autores: Debourdeau, Philippe, Bertoletti, Laurent, Font, C|||0000-0002-3547-7373, López Núñez, Juan José|||0000-0002-1226-2353, Gómez-Cuervo, Covadonga, Mahé, Isabelle|||0000-0003-1760-7880, Otero-Candelera, Remedios|||0000-0002-2265-1221, Adarraga, Maria Dolores, López-Miguel, Patricia|||0000-0001-5625-8201, Monreal, Manuel|||0000-0002-0494-0767
Tipo de recurso: artículo
Fecha de publicación:2023
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:281681
Acceso en línea:https://ddd.uab.cat/record/281681
https://dx.doi.org/urn:doi:10.3390/cancers15072034
Access Level:acceso abierto
Palabra clave:Anticoagulants
Cancers
Deep venous thrombosis
Prognosis
Superficial vein thrombosis
id ES_e6578b60a2c8f0fee0c36c5fcf61267f
oai_identifier_str oai:ddd.uab.cat:281681
network_acronym_str ES
network_name_str España
repository_id_str
spelling Three-Month Outcomes in Cancer Patients with Superficial or Deep Vein Thrombosis in the Lower LimbsResults from the RIETE RegistryDebourdeau, PhilippeBertoletti, LaurentFont, C|||0000-0002-3547-7373López Núñez, Juan José|||0000-0002-1226-2353Gómez-Cuervo, CovadongaMahé, Isabelle|||0000-0003-1760-7880Otero-Candelera, Remedios|||0000-0002-2265-1221Adarraga, Maria DoloresLópez-Miguel, Patricia|||0000-0001-5625-8201Monreal, Manuel|||0000-0002-0494-0767AnticoagulantsCancersDeep venous thrombosisPrognosisSuperficial vein thrombosisThe natural history of isolated lower-limb superficial vein thrombosis (SVT) in cancer patients is not well understood. To address this gap, we analyzed data from the RIETE registry, which included 110 cancer patients with isolated SVT, 1695 cancer patients with isolated deep vein thrombosis (DVT), and 1030 non-cancer patients with SVT. Compared to cancer patients with DVT, cancer patients with lower-limb SVT received lower doses of anticoagulants, had similar rates of subsequent pulmonary embolism (PE), DVT or SVT, were less likely to have metastases and had a lower mortality rate. However, cancer patients with lower-limb SVT had a higher rate of subsequent PE, DVT or SVT than non-cancer patients with SVT. Additionally, in cancer patients with lower-limb SVT, almost all recurrences and bleeding occurred within the first three months. Background: The clinical characteristics and outcomes of cancer patients with lower-limb isolated superficial vein thrombosis (SVT) have not been consistently evaluated. Methods: We used data in the RIETE registry to compare the clinical characteristics and 90-day outcomes for patients with: (1) active cancer and lower-limb SVT; (2) active cancer and lower-limb deep vein thrombosis (DVT); (3) lower-limb SVT without cancer. The primary outcomes included subsequent symptomatic SVT, DVT or pulmonary embolism (PE). Secondary outcomes were major bleeding and death. Results: From March 2015 to April 2021, there were 110 patients with cancer and SVT, 1695 with cancer and DVT, and 1030 with SVT but no cancer. Most patients in all subgroups (93%, 99% and 96%, respectively) received anticoagulants, while those with SVT received lower daily doses of low-molecular-weight heparin (114 ± 58, 163 ± 44, and 106 ± 50 IU/kg, respectively). During the first 90 days, 101 patients (3.6%) developed subsequent VTE (PE 47, DVT 41, SVT 13), whereas 72 (2.5%) had major bleeding and 282 (9.9%) died. Among the three groups, 90-day events were, respectively: VTE at rates of 7.3%, 4.0% and 2.4%; major bleeding at rates of 2.7%, 3.9% and 0.3%; mortality at rates of 8.2%, 16% and 0.3%. Between D90 and D180, only one SVT recurrence and one death occurred in SVT cancer patients. In multivariable analysis, cancer was associated with subsequent VTE (HR = 2.04; 1.15-3.62), while initial presentation as SVT or DVT were not associated with a different risk. Conclusions: The risk for subsequent VTE (including symptomatic SVT, DVT or PE) was similar in cancer patients with isolated SVT than in those with isolated DVT.Universitat Autònoma de Barcelona 22023-01-0120232023-01-01Articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/281681https://dx.doi.org/urn:doi:10.3390/cancers15072034reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.https://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:2816812026-06-06T12:50:31Z
dc.title.none.fl_str_mv Three-Month Outcomes in Cancer Patients with Superficial or Deep Vein Thrombosis in the Lower Limbs
Results from the RIETE Registry
title Three-Month Outcomes in Cancer Patients with Superficial or Deep Vein Thrombosis in the Lower Limbs
spellingShingle Three-Month Outcomes in Cancer Patients with Superficial or Deep Vein Thrombosis in the Lower Limbs
Debourdeau, Philippe
Anticoagulants
Cancers
Deep venous thrombosis
Prognosis
Superficial vein thrombosis
title_short Three-Month Outcomes in Cancer Patients with Superficial or Deep Vein Thrombosis in the Lower Limbs
title_full Three-Month Outcomes in Cancer Patients with Superficial or Deep Vein Thrombosis in the Lower Limbs
title_fullStr Three-Month Outcomes in Cancer Patients with Superficial or Deep Vein Thrombosis in the Lower Limbs
title_full_unstemmed Three-Month Outcomes in Cancer Patients with Superficial or Deep Vein Thrombosis in the Lower Limbs
title_sort Three-Month Outcomes in Cancer Patients with Superficial or Deep Vein Thrombosis in the Lower Limbs
dc.creator.none.fl_str_mv Debourdeau, Philippe
Bertoletti, Laurent
Font, C|||0000-0002-3547-7373
López Núñez, Juan José|||0000-0002-1226-2353
Gómez-Cuervo, Covadonga
Mahé, Isabelle|||0000-0003-1760-7880
Otero-Candelera, Remedios|||0000-0002-2265-1221
Adarraga, Maria Dolores
López-Miguel, Patricia|||0000-0001-5625-8201
Monreal, Manuel|||0000-0002-0494-0767
author Debourdeau, Philippe
author_facet Debourdeau, Philippe
Bertoletti, Laurent
Font, C|||0000-0002-3547-7373
López Núñez, Juan José|||0000-0002-1226-2353
Gómez-Cuervo, Covadonga
Mahé, Isabelle|||0000-0003-1760-7880
Otero-Candelera, Remedios|||0000-0002-2265-1221
Adarraga, Maria Dolores
López-Miguel, Patricia|||0000-0001-5625-8201
Monreal, Manuel|||0000-0002-0494-0767
author_role author
author2 Bertoletti, Laurent
Font, C|||0000-0002-3547-7373
López Núñez, Juan José|||0000-0002-1226-2353
Gómez-Cuervo, Covadonga
Mahé, Isabelle|||0000-0003-1760-7880
Otero-Candelera, Remedios|||0000-0002-2265-1221
Adarraga, Maria Dolores
López-Miguel, Patricia|||0000-0001-5625-8201
Monreal, Manuel|||0000-0002-0494-0767
author2_role author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Universitat Autònoma de Barcelona
dc.subject.none.fl_str_mv Anticoagulants
Cancers
Deep venous thrombosis
Prognosis
Superficial vein thrombosis
topic Anticoagulants
Cancers
Deep venous thrombosis
Prognosis
Superficial vein thrombosis
description The natural history of isolated lower-limb superficial vein thrombosis (SVT) in cancer patients is not well understood. To address this gap, we analyzed data from the RIETE registry, which included 110 cancer patients with isolated SVT, 1695 cancer patients with isolated deep vein thrombosis (DVT), and 1030 non-cancer patients with SVT. Compared to cancer patients with DVT, cancer patients with lower-limb SVT received lower doses of anticoagulants, had similar rates of subsequent pulmonary embolism (PE), DVT or SVT, were less likely to have metastases and had a lower mortality rate. However, cancer patients with lower-limb SVT had a higher rate of subsequent PE, DVT or SVT than non-cancer patients with SVT. Additionally, in cancer patients with lower-limb SVT, almost all recurrences and bleeding occurred within the first three months. Background: The clinical characteristics and outcomes of cancer patients with lower-limb isolated superficial vein thrombosis (SVT) have not been consistently evaluated. Methods: We used data in the RIETE registry to compare the clinical characteristics and 90-day outcomes for patients with: (1) active cancer and lower-limb SVT; (2) active cancer and lower-limb deep vein thrombosis (DVT); (3) lower-limb SVT without cancer. The primary outcomes included subsequent symptomatic SVT, DVT or pulmonary embolism (PE). Secondary outcomes were major bleeding and death. Results: From March 2015 to April 2021, there were 110 patients with cancer and SVT, 1695 with cancer and DVT, and 1030 with SVT but no cancer. Most patients in all subgroups (93%, 99% and 96%, respectively) received anticoagulants, while those with SVT received lower daily doses of low-molecular-weight heparin (114 ± 58, 163 ± 44, and 106 ± 50 IU/kg, respectively). During the first 90 days, 101 patients (3.6%) developed subsequent VTE (PE 47, DVT 41, SVT 13), whereas 72 (2.5%) had major bleeding and 282 (9.9%) died. Among the three groups, 90-day events were, respectively: VTE at rates of 7.3%, 4.0% and 2.4%; major bleeding at rates of 2.7%, 3.9% and 0.3%; mortality at rates of 8.2%, 16% and 0.3%. Between D90 and D180, only one SVT recurrence and one death occurred in SVT cancer patients. In multivariable analysis, cancer was associated with subsequent VTE (HR = 2.04; 1.15-3.62), while initial presentation as SVT or DVT were not associated with a different risk. Conclusions: The risk for subsequent VTE (including symptomatic SVT, DVT or PE) was similar in cancer patients with isolated SVT than in those with isolated DVT.
publishDate 2023
dc.date.none.fl_str_mv 2
2023-01-01
2023
2023-01-01
dc.type.none.fl_str_mv Article
http://purl.org/coar/resource_type/c_6501
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://ddd.uab.cat/record/281681
https://dx.doi.org/urn:doi:10.3390/cancers15072034
url https://ddd.uab.cat/record/281681
https://dx.doi.org/urn:doi:10.3390/cancers15072034
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Dipòsit Digital de Documents de la UAB
instname:Universitat Autònoma de Barcelona
instname_str Universitat Autònoma de Barcelona
reponame_str Dipòsit Digital de Documents de la UAB
collection Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869422757862703104
score 15,300719

Similares en LA Referencia